[go: up one dir, main page]

BRPI0905946B8 - anel intravaginal monolítico e processo para a produção de um anel intravaginal monolítico - Google Patents

anel intravaginal monolítico e processo para a produção de um anel intravaginal monolítico

Info

Publication number
BRPI0905946B8
BRPI0905946B8 BRPI0905946A BRPI0905946A BRPI0905946B8 BR PI0905946 B8 BRPI0905946 B8 BR PI0905946B8 BR PI0905946 A BRPI0905946 A BR PI0905946A BR PI0905946 A BRPI0905946 A BR PI0905946A BR PI0905946 B8 BRPI0905946 B8 BR PI0905946B8
Authority
BR
Brazil
Prior art keywords
intravaginal ring
monolithic intravaginal
producing
monolithic
ring
Prior art date
Application number
BRPI0905946A
Other languages
English (en)
Inventor
Mahashabde Anu
D Harrison Diane
Tsao Jiaxiang
U Ahmed Salah
Original Assignee
Ferring Bv
Ferring Int Center Sa
Teva Womens Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40939073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0905946(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv, Ferring Int Center Sa, Teva Womens Health Inc filed Critical Ferring Bv
Publication of BRPI0905946A2 publication Critical patent/BRPI0905946A2/pt
Publication of BRPI0905946B1 publication Critical patent/BRPI0905946B1/pt
Publication of BRPI0905946B8 publication Critical patent/BRPI0905946B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/08—Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception, e.g. combined with devices protecting against contagion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C45/00—Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mould; Apparatus therefor
    • B29C45/0001—Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mould; Apparatus therefor characterised by the choice of material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C45/00—Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mould; Apparatus therefor
    • B29C45/17—Component parts, details or accessories; Auxiliary operations
    • B29C45/72—Heating or cooling
    • B29C45/7207—Heating or cooling of the moulded articles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2083/00—Use of polymers having silicon, with or without sulfur, nitrogen, oxygen, or carbon only, in the main chain, as moulding material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
    • B29K2105/0035—Medical or pharmaceutical agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
    • B29L2031/00—Other particular articles
    • B29L2031/753—Medical equipment; Accessories therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Mechanical Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Surgical Instruments (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

uso de um anel intravaginal monolítico, anel intravaginal monolítico e processo para a produção de um anel intravaginal monolítico. a presente invenção relaciona-se a anéis intravaginais monolíticos que compreendem progesterona, a métodos de produção e usos dos mesmos. os anéis intravaginais compreendem progesterona, um elastômero de polisiloxano, e um hidrocarboneto farmaceuticamente aceitável ou ésteres de glicerol de um ácido graxo.
BRPI0905946A 2008-02-04 2009-02-03 anel intravaginal monolítico e processo para a produção de um anel intravaginal monolítico BRPI0905946B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2611508P 2008-02-04 2008-02-04
US61/026,115 2008-02-04
US13945408P 2008-12-19 2008-12-19
US61/139,454 2008-12-19
PCT/US2009/000672 WO2009099586A2 (en) 2008-02-04 2009-02-03 Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof

Publications (3)

Publication Number Publication Date
BRPI0905946A2 BRPI0905946A2 (pt) 2015-06-30
BRPI0905946B1 BRPI0905946B1 (pt) 2020-09-29
BRPI0905946B8 true BRPI0905946B8 (pt) 2021-05-25

Family

ID=40939073

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0905946A BRPI0905946B8 (pt) 2008-02-04 2009-02-03 anel intravaginal monolítico e processo para a produção de um anel intravaginal monolítico

Country Status (26)

Country Link
US (5) US8580293B2 (pt)
EP (2) EP2359807B1 (pt)
JP (2) JP5507467B2 (pt)
KR (3) KR101730517B1 (pt)
CN (2) CN102098991B (pt)
AR (1) AR070561A1 (pt)
AU (1) AU2009210779B2 (pt)
BR (1) BRPI0905946B8 (pt)
CA (2) CA2713943C (pt)
CL (1) CL2009000242A1 (pt)
DK (2) DK2249757T3 (pt)
EA (2) EA021615B1 (pt)
ES (2) ES2648640T3 (pt)
HR (1) HRP20171319T1 (pt)
HU (1) HUE035634T2 (pt)
IL (2) IL207376A (pt)
LT (1) LT2249757T (pt)
MX (2) MX385981B (pt)
NZ (3) NZ596844A (pt)
PL (2) PL2359807T3 (pt)
PT (2) PT2359807T (pt)
SG (2) SG187529A1 (pt)
SI (2) SI2249757T1 (pt)
TW (3) TWI549681B (pt)
WO (1) WO2009099586A2 (pt)
ZA (2) ZA201307320B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2648640T3 (es) 2008-02-04 2018-01-04 Ferring B.V. Anillos intravaginales monolíticos que comprenden progesterona y métodos de fabricación y usos de los mismos
CA2803874A1 (en) * 2010-06-22 2011-12-29 Anu Mahashabde Intravaginal devices comprising anticholinergic agents, and methods of making thereof
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
EP2641602A1 (en) * 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
ES2787882T3 (es) 2013-02-08 2020-10-19 Qpharma Ab Un dispositivo intravaginal, y un método para reducir la velocidad de difusión de ingredientes activos en dicho dispositivo intravaginal
CN103445892A (zh) * 2013-08-02 2013-12-18 苏州市马尔泰新材料有限公司 一种含有甲酯树脂和雌酚的阴道模具
CN103431930A (zh) * 2013-08-02 2013-12-11 苏州市马尔泰新材料有限公司 一种含有甲酯树脂的阴道模具
CN103405810A (zh) * 2013-08-02 2013-11-27 苏州市马尔泰新材料有限公司 一种含有甲基丙烯酸甲酯树脂的阴道模具
CN103394127A (zh) * 2013-08-02 2013-11-20 苏州市马尔泰新材料有限公司 一种含有中西医药的阴道模具材料
CN103394128A (zh) * 2013-08-02 2013-11-20 苏州市马尔泰新材料有限公司 一种含有川芎的模具材料
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
PT3125964T (pt) 2014-04-01 2024-09-09 Poly Med Inc Contracetivo e dispositivo relacionado
CN105392454B (zh) 2014-06-28 2018-05-08 安德罗玛克实验室股份有限公司 用于预防早产的含有延长、不变和持续释放的孕酮的环扎子宫托
CN104546267B (zh) * 2015-01-13 2017-01-04 安徽农业大学 一种犬用宫外节育装置及其节育方法
CA3008940A1 (en) * 2015-12-21 2017-06-29 Bayer Oy A method of manufacturing a vaginal ring
EP3542786A1 (en) * 2018-03-21 2019-09-25 ITF Research Pharma, S.L.U. Progesterone intravaginal devices
CA3135362A1 (en) * 2019-03-29 2020-10-08 Bridget MARTELL Eva segmented intravaginal rings containing progesterone
US10918649B2 (en) 2019-06-21 2021-02-16 The Population Council, Inc. System for providing birth control
US11439588B2 (en) 2019-10-12 2022-09-13 National Research Institute For Family Planning Vaginal sustained-release drug delivery system for luteal support, method for preparation and use thereof
US20220186312A1 (en) * 2020-12-11 2022-06-16 Guzip Biomarkers Corporation Predictive method for assessing the success of embryo implantation

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE494972A (pt) 1949-04-07
US2863846A (en) 1950-05-04 1958-12-09 Dow Corning Organo silyl-silica filled siloxane elastomers and process for producing same
US2890188A (en) 1951-12-17 1959-06-09 Dow Corning Siloxane elastomers compounded with hydroxylated silanes
NL91756C (pt) 1953-11-19
US3022951A (en) 1957-05-14 1962-02-27 Ibm Full adder
US3545439A (en) 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3948262A (en) 1969-04-01 1976-04-06 Alza Corporation Novel drug delivery device
IL48277A (en) 1974-10-18 1978-03-10 Schering Ag Vaginal ring
DE3040978A1 (de) 1980-10-28 1982-05-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen Vaginalring
US4629449A (en) 1982-07-29 1986-12-16 Alza Corporation Vaginal dispenser for dispensing beneficial hormone
US4816257A (en) 1985-09-20 1989-03-28 Research & Education Institute, Harbor-Ucla Medical Center Inc. Method for producing an in vivo environment suitable for human embryo transfer
US5188835A (en) * 1986-06-16 1993-02-23 Kabi Pharmacia Ab Intravaginal devices
SE8602666D0 (sv) * 1986-06-16 1986-06-16 Leo Ab Intravaginal devices
FR2618329B1 (fr) 1987-07-22 1997-03-28 Dow Corning Sa Procede de fabrication d'un anneau capable d'assurer la liberation d'un agent therapeutique, et anneau fabrique par ce procede
US5084277A (en) 1988-08-30 1992-01-28 Greco John C Vaginal progesterone tablet
US5116619A (en) 1988-08-30 1992-05-26 Lee Roy Morgan Vaginal progesterone tablet
DE3838815A1 (de) 1988-11-17 1990-05-23 Hoechst Ag Verfahren zum herstellen eines intravaginalen applikationssystems
US6264638B1 (en) 1989-12-07 2001-07-24 Ultrafem, Inc. Intravaginal drug delivery system and discharge collection device
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5393528A (en) 1992-05-07 1995-02-28 Staab; Robert J. Dissolvable device for contraception or delivery of medication
IT1256393B (it) 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
FI95768C (fi) 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6544546B1 (en) 1995-07-04 2003-04-08 Akzo Nobel, N.V. Ring-shaped devices
GB9522403D0 (en) 1995-11-01 1996-01-03 Hoechst Roussel Ltd Intravaginal drug delivery device
US5744463A (en) 1996-06-03 1998-04-28 Bair; Glenn O. Treatment of side effects of progestins and progesterone analogues used for birth control
US5869081A (en) 1996-06-28 1999-02-09 The Population Council Progesterone vaginal ring for treatment of infertility
US5972372A (en) 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US5985861A (en) 1996-11-04 1999-11-16 Columbia Laboratories, Inc. Progesterone for treating or reducing ischemia
US5814329A (en) 1996-11-12 1998-09-29 Polytherapeutics, Inc. Hydrophilic polystyrene graft copolymer vehicle for intravaginal administration of pharmacologically active agents
US5993856A (en) 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
US6416778B1 (en) 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US6056972A (en) 1997-02-26 2000-05-02 Dimera, Llc Method for reducing coronary artery reactivity
CA2288046C (en) * 1997-05-07 2006-10-03 Galen (Chemicals) Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
US6197327B1 (en) * 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
US6039968A (en) 1997-06-24 2000-03-21 Hoechst Marion Roussel Intravaginal drug delivery device
US6245757B1 (en) 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
US6306914B1 (en) 1997-10-21 2001-10-23 Columbia Laboratories, Inc. Progestin therapy for maintaining amenorrhea
NZ330596A (en) 1998-06-05 2001-02-23 Dec Res Intravaginal devices allowing for increased uptake of active ingredients
US6394094B1 (en) 1998-05-01 2002-05-28 Enhance Pharmaceuticals, Inc. Method for injection molding manufacture of controlled release devices
JP2002518351A (ja) 1998-06-19 2002-06-25 オキシバイオ・インコーポレイテッド 抗感染および避妊特性を有する医療装置
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
US6056976A (en) 1998-11-12 2000-05-02 Leiras Oy Elastomer, its preparation and use
US6063395A (en) 1998-11-12 2000-05-16 Leiras Oy Drug delivery device especially for the delivery of progestins and estrogens
US20050197651A1 (en) 2001-04-25 2005-09-08 Chen Hai L. Vaginal ring preparation and its application
CN1210079C (zh) 2001-04-25 2005-07-13 上海市计划生育科学研究所 阴道环制剂及其应用
JP2005503389A (ja) * 2001-08-31 2005-02-03 シエーリング オサケユイチア 薬物送達システム
WO2003065924A1 (en) 2002-02-08 2003-08-14 Advanced Animal Technology Limited Control of a biological function
AU2003226746A1 (en) * 2002-03-27 2003-10-08 Galen (Chemicals) Limited Intravaginal matrix drug delivery devices
BR0315194A (pt) 2002-10-31 2005-08-23 Umd Inc Composições terapêuticas para liberação de droga para a, e através da, cobertura epitelial
US20040089308A1 (en) 2002-11-13 2004-05-13 Welch Robert A. Cervical ring to deliver medication
FR2849380A1 (fr) 2002-12-27 2004-07-02 Ernest Loumaye NOUVELLE UTILISATION D'UN AGONISTE DU GnRH
ATE461681T1 (de) 2003-04-29 2010-04-15 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
US8404272B2 (en) 2003-06-26 2013-03-26 Poly-Med, Inc. Fiber-reinforced composite rings for intravaginal controlled drug delivery
WO2005004837A1 (en) 2003-07-10 2005-01-20 Galen (Chemicals) Limited Intravaginal drug delivery devices
US20050255157A1 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Sustained release, mucoadhesive vaginal pharmaceutical compositions
US7707169B2 (en) 2004-06-10 2010-04-27 Siemens Corporation Specification-based automation methods for medical content extraction, data aggregation and enrichment
MX2007000273A (es) 2004-07-09 2007-05-21 Population Council Inc Composiciones de liberacion sostenida que contiene moduladores del receptor de progesterona.
AR043476A1 (es) 2004-09-09 2005-08-03 Dvoskin Victor Oscar Dispositivo de administracion regulada de sustancias para la insercion en una cavidad corporal y procedimiento para fabricar un medio de soporte de dichas sustancias
US7517914B2 (en) 2005-04-04 2009-04-14 Boston Scientificscimed, Inc. Controlled degradation materials for therapeutic agent delivery
US8399012B2 (en) 2006-04-17 2013-03-19 Kimberly-Clark Worldwide, Inc. Degradable therapeutic delivery device
EP2023898A1 (en) 2006-05-10 2009-02-18 Evonik Degussa GmbH Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
US20080214512A1 (en) 2007-03-01 2008-09-04 Christian Seitz Pharmaceutical preparation containing a gestagen, and kit and method for treating endometriosis using the preparation
EP3607937A1 (en) 2007-03-22 2020-02-12 Berg LLC Topical formulations having enhanced bioavailability
EP2150271A1 (en) 2007-05-11 2010-02-10 The Texas A & M Univsersity System Hormone normalization therapy and uses thereof
ES2648640T3 (es) 2008-02-04 2018-01-04 Ferring B.V. Anillos intravaginales monolíticos que comprenden progesterona y métodos de fabricación y usos de los mismos

Also Published As

Publication number Publication date
NZ611268A (en) 2015-03-27
LT2249757T (lt) 2017-09-25
US10548904B2 (en) 2020-02-04
US20160279147A1 (en) 2016-09-29
ZA201307320B (en) 2017-03-29
KR20160055980A (ko) 2016-05-18
TW201630610A (zh) 2016-09-01
SI2249757T1 (sl) 2017-10-30
CN102098991B (zh) 2014-10-22
PT2359807T (pt) 2017-11-07
HUE035634T2 (en) 2018-05-28
JP5507467B2 (ja) 2014-05-28
CL2009000242A1 (es) 2010-01-04
EP2249757B1 (en) 2017-08-09
AU2009210779B2 (en) 2015-04-02
AR070561A1 (es) 2010-04-21
TWI599359B (zh) 2017-09-21
NZ587758A (en) 2012-05-25
US8580293B2 (en) 2013-11-12
SG187529A1 (en) 2013-02-28
KR101730517B1 (ko) 2017-04-26
US20230158044A1 (en) 2023-05-25
WO2009099586A3 (en) 2010-01-14
KR20140048321A (ko) 2014-04-23
JP2014167001A (ja) 2014-09-11
MX337634B (es) 2016-03-14
DK2249757T3 (en) 2017-10-16
TW200938204A (en) 2009-09-16
US10537584B2 (en) 2020-01-21
CA2713943A1 (en) 2009-08-13
EA201491815A1 (ru) 2015-03-31
HRP20171319T1 (hr) 2017-10-20
WO2009099586A2 (en) 2009-08-13
IL207376A (en) 2012-09-24
BRPI0905946A2 (pt) 2015-06-30
TWI549681B (zh) 2016-09-21
IL221988A (en) 2015-03-31
EP2359807A1 (en) 2011-08-24
IL207376A0 (en) 2010-12-30
CA3016642A1 (en) 2009-08-13
DK2359807T3 (en) 2017-10-16
CA2713943C (en) 2018-10-23
SI2359807T1 (sl) 2017-10-30
PL2249757T3 (pl) 2017-12-29
MX2010008545A (es) 2010-12-20
EP2359807B1 (en) 2017-07-26
ES2648640T3 (es) 2018-01-04
US20140030311A1 (en) 2014-01-30
ZA201307321B (en) 2017-09-27
KR20100133969A (ko) 2010-12-22
EP2249757A2 (en) 2010-11-17
TW201526898A (zh) 2015-07-16
PL2359807T3 (pl) 2017-12-29
MX385981B (es) 2025-03-04
TWI655947B (zh) 2019-04-11
CN104146948B (zh) 2018-01-02
US20200405732A1 (en) 2020-12-31
CN102098991A (zh) 2011-06-15
US11413294B2 (en) 2022-08-16
PT2249757T (pt) 2017-11-15
BRPI0905946B1 (pt) 2020-09-29
EA021615B1 (ru) 2015-07-30
NZ596844A (en) 2014-03-28
JP2011510984A (ja) 2011-04-07
ES2645630T3 (es) 2017-12-07
EP2249757A4 (en) 2011-07-20
EA031017B1 (ru) 2018-11-30
US20090202612A1 (en) 2009-08-13
JP6124411B2 (ja) 2017-05-10
SG10201605171QA (en) 2016-08-30
EA201070919A1 (ru) 2011-04-29
CN104146948A (zh) 2014-11-19
AU2009210779A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
BRPI0905946B8 (pt) anel intravaginal monolítico e processo para a produção de um anel intravaginal monolítico
CY1114687T1 (el) Παραγωγη σκουαλενιου απο υπερπαραγωγικους ζυμομυκητες
FI20075434A0 (fi) Prosessi haavoittuneiden hiilivetyjen valmistamiseksi
BR112015000534A8 (pt) “método para a preparação de 2,4-dihidroxibutirato, microrganismo modificado e método de produção de 2,4-dhb”
CO6501190A2 (es) Vacuna de pcsk9
BR112012007085B8 (pt) processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila
MX339640B (es) Derivados de 5, 6-dihidro-2h-[1, 4] oxazin-3-il-amina utiles como inhibidores de la beta-secretasa (bace).
CO6430501A2 (es) Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, método para la preparación de los mismos y composición farmacéutica que los contiene
MX2012008388A (es) Microorganismos productores de acido eicosapentenoico, composiciones de acido graso, y metodos de elaboracion y usos de los mismos.
BR112015017606A2 (pt) composição, método de produzir a composição, utilização da composição e combustível obtido a partir da composição
BR112013023517A2 (pt) "inibidores de produção de leucotrieno, seus usos, e composição farmacêutica"
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
BR112012020058A2 (pt) preparação de benzofuranos e uso dos mesmos como intermediários sintéticos.
BRPI0920048A2 (pt) Metodo para produzir etil esteres de ácido graxo, reutilização de pelo menos uma enzima lipolítica imobilizada em um carreador hidrofílico, composição, uso da composição, e, combustível
BR112012024413A2 (pt) método de tratamento e utilização de piche de tall oil
MX2016000794A (es) Composiciones farmaceuticas de pancreatina de potencia alta.
BR112016000658A2 (pt) pancreatina de alta atividade, processo para a preparação de pancreatina de aa tendo atividade lipásica específica de pelo menos aproximadamente 120 usp iu/mg e método de tratamento de um paciente sujeito a uma condição patológica associada com a insuficiência enzimática pandreática
MX390947B (es) Composiciones terapéuticas de ceramidasa ácida y métodos para prepararlas y utilizarlas.
CL2012002246A1 (es) Proceso para producir un extracto de alergenos; extracto de alergenos; uso de un extracto de alergenos para tratar alergia a los cacahuetes; composicion farmacéutica que comprende dicho extracto; vacuna que comprende un extracto de alergenos.
BR112017007949A2 (pt) método para produção de álcool pelo uso de uma tripeptidil-peptidase
BR112012017485A2 (pt) derivados de ácido carboxílico tendo um anel de oxazolpirimidina 2.5.7-substituído
FR2967084B1 (fr) Procede de production d'une composition emulsifiante a base de lecithine hdrogenee
BR112013012947A2 (pt) uso de ésteres como agente de coalescência
BR112012007577A2 (pt) semigéis de ácido silícico de superfície modificada
BRPI0713342A2 (pt) Composições e kits compreendendo um componente de melatonina e um componente de ácido graxo ômega -3

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: FERRING INTERNATIONAL CENTER S.A. (CH)

B25A Requested transfer of rights approved

Owner name: FERRING B.V. (NL)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/02/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.